Abstract:Alzheimer's disease (AD) is a neurodegenerative disease affecting mental ability and neurocognitive functions. Cholinesterase enzymes affect concentration of acetylcholine in the brain, leading to dementia. Thus, there is an urgent need to develop novel dual cholinesterase inhibitors as possible anti-AD drugs. Herein, we have designed and synthesized a novel series of 9 H -carbazole-4 H -chromenes 4 ( a-l ) through a one-pot three-component reaction of salicylaldehydes (1) , hydroxycarbazole (2) and N -methyl-1-(methylthio)-2-nitroethenamine (3) using triethylamine as a catalyst in ethanol. Synthetic transformation involves the formation of two C–C bonds and one C–O bond in a single step to obtain desired analogs. The rapid one-pot reaction does not require chromatographic purification, proceeds under mild conditions, and exhibits good tolerance toward various functional groups with high synthetic yields. Synthesized compounds were screened for cytotoxicity using MTT assay in BV-2 microglial cells. These compounds were then in-vitro screened against acetylcholinesterase (AChE) and butyrylcholinestrase (BuChE) enzymes. Most of these ligands have shown dual cholinesterase inhibitory activity compared to the standard drug. In-vitro results showed that the compounds 4a and 4d have promising anticholinesterase response against both cholinesterase enzymes ( 4a , AChE IC 50 : 5.76 μM, BuChE IC 50 : 48.98 μM; 4d , AChE IC 50 : 3.58 μM, BuChE IC 50 : 42.73 μM). In-vitro results were validated by molecular docking and dynamic simulation at 100 ns. Molecular docking and molecular dynamics simulation study strongly supported structural features present in these analogs. Together, these analogs could be exploited to develop dual anti-cholinesterase candidates to treat AD in combination with other drugs.

Optical control of butyrylcholinesterase (BChE) activity via photoswitchable azobenzene for potential treatment of Alzheimer's disease

Optical Control of Butyrylcholinesterase (bche) Activity Via Photoswitchable Azobenzene for Potential Treatment of Alzheimer’s Disease

Discovery, Structure-Based Modification, in Vitro, in Vivo, and in Silico Exploration of M-Sulfamoyl Benzoamide Derivatives As Selective Butyrylcholinesterase Inhibitors for Treating Alzheimer's Disease.

Discovery, Structure-Based Modification, In Vitro , In Vivo , and In Silico Exploration of m -Sulfamoyl Benzoamide Derivatives as Selective Butyrylcholinesterase Inhibitors for Treating Alzheimer’s Disease

Design, synthesis and biological evaluation of novel pyrazolone derivatives as selective butyrylcholinesterase inhibitors with antioxidant activity against Alzheimer's disease

Treatment of Alzheimer's disease with small-molecule photosensitizers

Design, Synthesis, and Biological Evaluation of Scutellarein Carbamate Derivatives As Potential Multifunctional Agents for the Treatment of Alzheimer's Disease

Synthesis and bio-evaluation of a novel selective butyrylcholinesterase inhibitor discovered through structure-based virtual screening

Discovery of Selective Butyrylcholinesterase (BChE) Inhibitors through a Combination of Computational Studies and Biological Evaluations.

Rapid Discovery and Crystallography Study of Highly Potent and Selective Butylcholinesterase Inhibitors Based on Oxime-Containing Libraries and Conformational Restriction Strategies

Optimizing Drug-Like Properties of Selective Butyrylcholinesterase Inhibitors for Cognitive Improvement: Enhancing Aqueous Solubility by Disrupting Molecular Plane

Bioinspired Design of Highly Specific Fluorescent Probe for Butyrylcholinesterase Imaging in Living Cells and Alzheimer's Disease Model

Design, Synthesis, Biological Evaluation and Molecular Modeling of N-isobutyl-N-((2-(p-tolyloxymethyl)thiazol-4yl)methyl)benzo[d][1,3] Dioxole-5-carboxamides As Selective Butyrylcholinesterase Inhibitors.

Design, synthesis and biological evaluation of novel pyrazolinone derivatives as multifunctional ligands for the treatment of Alzheimer's disease

Design, synthesis, and biological evaluation of aromatic tertiary amine derivatives as selective butyrylcholinesterase inhibitors for the treatment of Alzheimer's disease

Discovery of New Selective Butyrylcholinesterase (BChE) Inhibitors with Anti-Aβ Aggregation Activity: Structure-Based Virtual Screening, Hit Optimization and Biological Evaluation

Recent Progress in Regulating the Activity of Enzymes with Photoswitchable Inhibitors

Design, Synthesis, and Biological Evaluation of Novel Chromanone Derivatives as Multifunctional Agents for the Treatment of Alzheimer's Disease

Deuteration as a General Strategy to Enhance Azobenzene‐Based Photopharmacology

Development of novel 9H-carbazole-4H-chromene hybrids as dual cholinesterase inhibitors for the treatment of Alzheimer's disease

Selective Pseudo-irreversible Butyrylcholinesterase Inhibitors Transferring Antioxidant Moieties to the Enzyme Show Pronounced Neuroprotective Efficacy In Vitro and In Vivo in an Alzheimer’s Disease Mouse Model